Drugs / MN-08
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05660863 | Sep 2025 → Mar 2026 overdue | pulmonary arterial hypertension | Guangzhou Magpie Pharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MN-08 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05660863 ↗ |